Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

This study highlighted the promising health benefits of taxifolin, a flavonoid with antioxidant, anti-inflammatory, and other protective effects found in foods like onions and milk thistle, though more research is needed to fully understand its mechanisms and safety for human therapeutic use.

In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.

This study identified distinct plasma miRNA profiles in alopecia areata that may aid in diagnosis and therapy, but further validation is needed to confirm these exploratory findings.

This study reviews advances in targeted therapies for moderate-severe dermatological conditions like plaque psoriasis and atopic dermatitis, reporting on newly approved treatments and highlighting the need for further innovations in managing rare inflammatory skin diseases through emerging laboratory techniques and trials.

This study describes vitiligo as an autoimmune disease marked by depigmented skin and mucosal patches, and reviews its complex pathogenesis and diagnostic features. Treatment aims for disease control and repigmentation through various topical and systemic therapies, phototherapy, and surgical options, emphasizing personalized, multimodal approaches.

In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy. Discontinuation of rituximab and initiation of oral baricitinib led to improvement in skin conditions, underscoring potential immune-related skin effects from rituximab.

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

This study suggests that 9-Octadecenoic acid (Z)-, 2,3-dihydroxypropyl ester from African Yam bean seeds may inhibit the human 5α-reductase II enzyme, potentially helping manage BPH, although further studies are needed.

This review discusses the molecular mechanisms and therapeutic effectiveness of Janus Kinase Inhibitors for inflammatory skin diseases, suggesting these inhibitors have a rapid onset and favorable safety profile compared to conventional treatments.

This review discusses the potential impact of lifestyle factors on the progression of androgenetic alopecia and reports no new clinical findings; the authors emphasize the need for more comprehensive studies.

Natural products might help treat hair greying.

This study on alopecia areata meta-analyses highlights the risk of misleading results when ineffective, unsafe, or unapproved dosing regimens are included, recommending methodological safeguards to ensure accurate data interpretation and avoid inappropriate causal inferences.

This review examines various pharmacological options for managing alopecia areata, highlighting the effectiveness of corticosteroids for mild to moderate cases and promising results from JAK inhibitors like baricitinib for more severe forms, with additional benefits from minoxidil and potential from other treatments.

This case study details a 44-year-old woman with rheumatoid arthritis and systemic lupus erythematosus who developed hypereosinophilic asthma and was initially treated as ANCA-negative eosinophilic granulomatosis with polyangiitis. Her condition, eventually classified as HASM, underscores the need for evaluating EGPA-spectrum disorders in similar scenarios.

This study analyzed 853 articles to reveal that research on silica-based nanobiomaterials in regenerative medicine has rapidly increased, with distinct regional differences in impact and emerging focus areas in drug delivery and wound healing.

This study identified a four-gene loop as a non-invasive biomarker that selectively activates in alopecia areata, providing a precise target for JAK inhibitor treatments.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study demonstrated that SHFKO significantly accelerated healing in acute radiation-induced skin injuries, with mechanisms involving apoptosis inhibition, suppression of inflammation, and restoration of ROS balance, suggesting its potential as a novel multi-target therapy for radiodermatitis.

The hydrogel helps heal wounds without scars by releasing two drugs gradually.

This review reports that Fenugreek seeds contain compounds like Galactomannan and Trigonelline, which show anti-diabetic and anti-hyperlipidemic effects, while Fenugreek leaves have high saponin content, contributing to their anti-microbial activities.

This study suggests that elevated levels of IL-17A and IL-23 in alopecia areata may play roles in disease severity and activity, providing insights into potential therapeutic targets.

In this conference session, experts reviewed clinical evidence and strategies for using JAK inhibitors in managing alopecia areata, emphasizing optimal treatment practices and individual patient considerations to enhance safety and effectiveness in real-world settings.

This case report presents the first instance of a pediatric alopecia areata patient switching from baricitinib to ritlecitinib, demonstrating favorable clinical outcomes, suggesting a potential new treatment pathway for children with severe cases of this condition.

This review synthesizes recent research to propose a precision framework for treating androgenetic alopecia and alopecia areata based on genetic insights and pathway biology, highlighting the roles of androgen-receptor signaling, immune dysregulation, and emerging therapies like regenerative medicine and AI-assisted diagnostics.

In this prospective cohort, baseline severity, disease activity, and relapse history were identified as key factors influencing response and recurrence in alopecia areata, suggesting that implementing standardized assessments could enhance risk stratification and personalized care approaches.

The abstract does not provide any specific research findings or results, but rather serves as a promotional description for IP Innovative Publication Pvt Limited, highlighting their services and publication offerings in medical journals and related fields from Delhi, India.

This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.

In this study, the derivation of certain topological indices was used to represent the molecular structure of drugs for alopecia treatment, like Minoxidil and Finasteride, which may support medication investigations, especially in resource-limited settings.